A glass tube for pharmaceutical containers and a manufacturing process for a glass tube are provided. The glass tubes are characterized by a homogenous and low alkali leachability on the inner surface.

A glass tube for pharmaceutical containers and a process for the production of a glass tube are provided. The glass tubes have low alkali leachability and are devoid of a lamp ring.

A glass tube for pharmaceutical containers and a process for the production of a glass tube are provided. The glass tubes have low alkali leachability and are devoid of a lamp ring.

A borosilicate glass for a pharmaceutical container having high appearance quality, particularly a small number of air lines, and a glass tube for a pharmaceutical container are provided. The borosilicate glass for a pharmaceutical container contains, in mass %, from 70.0 to 78.0% of SiO.sub.2, from 5.0 to 8.0% of Al.sub.2O.sub.3, from 5.0 to 12.0% of B.sub.2O.sub.3, from 0 to 4.0% of CaO, from 0 to 4.0% of BaO, from 4.0 to 8.0% of Na.sub.2O, from 0 to 5.0% of K.sub.2O and from 0.001 to 1.0% of SnO.sub.2.

A borosilicate glass for a pharmaceutical container having high appearance quality, particularly a small number of air lines, and a glass tube for a pharmaceutical container are provided. The borosilicate glass for a pharmaceutical container contains, in mass %, from 70.0 to 78.0% of SiO.sub.2, from 5.0 to 8.0% of Al.sub.2O.sub.3, from 5.0 to 12.0% of B.sub.2O.sub.3, from 0 to 4.0% of CaO, from 0 to 4.0% of BaO, from 4.0 to 8.0% of Na.sub.2O, from 0 to 5.0% of K.sub.2O and from 0.001 to 1.0% of SnO.sub.2.

A glass for a pharmaceutical container of the present invention includes as a glass composition, in terms of mol %, 60% to 85% of SiO.sub.2, 3% to 20% of Al.sub.2O.sub.3, 0% to 5% of B.sub.2O.sub.3, 0% to 9% of Li.sub.2O, 0% to 12% of Na.sub.2O, 0% to 6% of K.sub.2O, 0.1% to 26% of Li.sub.2O+Na.sub.2O+K.sub.2O, 0% to 1% of SrO, and 0% to 1% of BaO, having a value for a molar ratio K.sub.2O/(Li.sub.2O+Na.sub.2O+K.sub.2O) of 0.60 or less, and having a value for a molar ratio Al.sub.2O.sub.3/(Li.sub.2O+Na.sub.2O+K.sub.2O) of 50 or less.

A glass for a pharmaceutical container of the present invention includes as a glass composition, in terms of mol %, 60% to 85% of SiO.sub.2, 3% to 20% of Al.sub.2O.sub.3, 0% to 5% of B.sub.2O.sub.3, 0% to 9% of Li.sub.2O, 0% to 12% of Na.sub.2O, 0% to 6% of K.sub.2O, 0.1% to 26% of Li.sub.2O+Na.sub.2O+K.sub.2O, 0% to 1% of SrO, and 0% to 1% of BaO, having a value for a molar ratio K.sub.2O/(Li.sub.2O+Na.sub.2O+K.sub.2O) of 0.60 or less, and having a value for a molar ratio Al.sub.2O.sub.3/(Li.sub.2O+Na.sub.2O+K.sub.2O) of 50 or less.

Compounds, compositions, articles, devices, and methods for the manufacture of light guide plates and back light units including such light guide plates made from glass. In some embodiments, light guide plates (LGPs) are provided that have similar or superior optical properties to light guide plates made from PMMA and that have exceptional mechanical properties such as rigidity, CTE and dimensional stability in high moisture conditions as compared to PMMA light guide plates.

Compounds, compositions, articles, devices, and methods for the manufacture of light guide plates and back light units including such light guide plates made from glass. In some embodiments, light guide plates (LGPs) are provided that have similar or superior optical properties to light guide plates made from PMMA and that have exceptional mechanical properties such as rigidity, CTE and dimensional stability in high moisture conditions as compared to PMMA light guide plates.

Glasses and glass products suitable for pharmaceutical packaging are provided and methods of making and using such glass and glass products are provided. The glasses combine chemical temperability with very good hydrolytic resistance as well as reduced color tinge. The invention also includes methods for the production of such glasses and their uses.